NCT03349034View on ClinicalTrials.gov

Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Head and Neck CancerFree Tissue Transfer
Interventions
DRUG

Ropivicaine

Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.

DRUG

Local Saline Infusion

Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.

Trial Locations (1)

10129

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03349034 - Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps | Biotech Hunter | Biotech Hunter